© 2025 HSP News Service, L.L.C.
In a study reported as a research letter in JAMA Network Open, Amboree identified U.S. counties with low or high cervical cancer screening coverage and associated risks of cervical cancer incidence and mortality. As stated by the investigators, “Recent research shows that cervical cancer incidence...
In a cross-sectional study reported in JAMA Network Open, Abel et al found that higher rates of neoadjuvant chemotherapy (NACT) and a higher annual volume of cytoreductive surgery were associated with better survival outcomes in patients treated at Commission on Cancer–accredited cancer programs in ...
In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...
In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with advanced ovarian and endometrial clear cell cancers. Study Details Twenty-eight patients with...
In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer. Study...
Despite advances in early cancer detection, racial and ethnic minority individuals seem to be more likely to have a late-stage diagnosis of cancers that have a recommended screening. A large study by the American Cancer Society that examined the association between neighborhood-level segregation...
This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of low-grade platinum-resistant ovarian cancer. The patient is a 75-year-old woman with a history of stage IIIB low-grade serous carcinoma that is BRCA wild-type and HRD proficient. She underwent six cycles of adjuvant carboplatin and paclitaxel, but did not receive maintenance therapy. Five months after her last cycle of chemotherapy, she presents with peritoneal carcinomatosis and a 5-cm liver mass. In the conversation that follows, the faculty emphasize the importance of routinely testing for hormone receptor expression in all cases of low-grade serous carcinoma, as well as the need for next-generation sequencing to determine the existence of potentially targetable KRAS mutations. They discuss the role of surgery and hormonal therapy in treating patients with low-grade serous disease, the clinical data supporting avutometinib plus defactinib for patients with KRAS mutations, and strategies for managing dermatologic toxicities.
This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of HER2-positive platinum-resistant ovarian cancer. The patient is a 45-year-old woman with a history of stage IVA high-grade serous ovarian cancer with BRCA1 mutation. She received six cycles of adjuvant carboplatin plus paclitaxel, followed by 2 years of maintenance olaparib after upfront cytoreductive surgery. She had two platinum-sensitive recurrences treated with different platinum-based combinations. She now presents with platinum-resistant progressive disease. Her archival tissue is tested, revealing HER2 0, folate receptor alpha 10%, and mismatch repair intact. In the conversation that follows, the faculty discuss the importance of obtaining fresh biopsies and retesting when deciding on targeted therapies for platinum-resistant disease, trastuzumab deruxtecan as a preferred treatment option for HER2-positive ovarian cancer, and management strategies for dealing with pneumonitis, a severe and potentially irreversible side effect of trastuzumab deruxtecan.
This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of high-grade platinum-resistant ovarian cancer that is folate receptor alpha (FRα) positive. The patient is a 65-year-old woman with a history of stage IIIC, BRCA wild-type, HRD-proficient, high-grade serous ovarian cancer. She underwent upfront cytoreductive surgery followed by six cycles of adjuvant carboplatin and paclitaxel. She developed platinum-sensitive recurrent disease and was subsequently treated with carboplatin, liposomal doxorubicin, and bevacizumab. Unfortunately, after six cycles of therapy, her restaging scans showed progressive disease. In the conversation that follows, the faculty discuss the importance of testing for FRα, the clinical data supporting mirvetuximab soravtansine as a first-line treatment option, and strategies to manage the ocular toxicities associated with this agent.
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...
Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine. Most guidelines currently recommend discontinuing...
Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations showed significantly improved survival when treated with immunotherapy compared with those without PPP2R1A mutations, according to study findings published in Nature. Preclinical findings from the study also suggested that...
Uterine cancer is the fourth most common cancer diagnosed in women in the United States, with about 69,120 new cases and nearly 14,000 deaths from the disease expected this year. Black women experience a twice as high mortality rate compared with women of other races and ethnicities, and that...
Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...
In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...
Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society. A number of significant independent risk factors for DVT...
Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503).
Climate change may be contributing to a small but notable increase in the incidence and mortality rates of breast, ovarian, endometrial, and cervical cancers in the Middle East and North Africa, according to a recent study published by Mataria and Chun in Frontiers in Public Health. Background...
Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine. Background Many...
Patients with a history of breast cancer who are carriers of BRCA1 and BRCA2 pathogenic variants benefit from undergoing bilateral salpingo-oophorectomy, the results of a retrospective cohort study published in The Lancet Oncology showed. Women who had their ovaries and fallopian tubes removed...
Teal Health announced the U.S. Food and Drug Administration’s (FDA) approval of the Teal Wand™, an at-home vaginal sample self-collection device for cervical cancer screening in the United States. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged ...
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have...
For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph node techniques. At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
A major international study, PORTEC-4a, provides evidence that molecular profiling may safely reduce the need for radiotherapy in some women with early-stage endometrial cancer while identifying those who would benefit from more intensive treatment. The results, presented at ESTRO 2025, may mark a...
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 1143)....
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
New research has revealed that Schistosoma haematobium, a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment. Presented at ESCMID Global 2025, this pivotal study sheds new light ...
The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...
In an analysis from the phase III MIRASOL trial reported in The Lancet Oncology, Van Gorp et al found no significant difference in quality of life between patients receiving mirvetuximab soravtansine vs chemotherapy for folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer. In...
The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inhibitor pembrolizumab and chemotherapy, followed by pembrolizumab plus maintenance with the PARP...
In an Israeli retrospective cohort study reported as a research letter in JAMA Network Open, Armon et al found that presymptomatic awareness of BRCA1/BRCA2 pathogenic variant carrier status was associated with better outcomes in several measures in women with ovarian cancer. Study Details The...
Investigators have found that nearly 50% of women diagnosed with ovarian cancer may not be receiving the genetic testing that could help guide their treatment and potentially improve outcomes, according to a recent report conducted by the Ovarian Cancer Research Alliance (OCRA) and Komodo Health....
In a study reported in JAMA Oncology, Agusti et al found that the addition of chemotherapy to adjuvant radiotherapy was not associated with improved overall survival in patients with intermediate-risk cervical cancer. Study Details The study involved National Cancer Database data on patients with a ...
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
In a study reported as a research letter in JAMA Network Open, Amboree et al found that women with cervical cancer living in rural U.S. counties had poorer outcomes than those living in urban counties. Study Details The trial used data from the National Program of Cancer Registries and...
Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...
A novel treatment approach may improve outcomes in patients with recurrent or metastatic cervical cancer, according to new findings presented by Choi et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Recurrent cervical cancer remains a significant challenge,...
Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Together, the two studies...
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....
Recent findings from the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT), which were published by Gargano et al in the Morbidity and Mortality Weekly Report, revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women....
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...